Low‐dose tipifarnib is a promising treatment to control GC with an aggressive phenotype that exhibits high HIF‐1α expression by regulating Rheb farnesylation, mTOR/HIF‐1α signaling, and ROS levels. The gene discussed is HIF1A; the disease is gastric cancer.